Post-Approval Study of the Neuspera Sacral Neuromodulation System

计划入组 116 人 · 首次发布于 2025 年 8 月 28 日

Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System

计划入组 30 人 · 首次发布于 2025 年 11 月 25 日

FREEDOM Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics

计划入组 100 人 · 首次发布于 2026 年 2 月 3 日

CAR T-cell therapy (sacral tumor)

PTM-101

Cell-based trivalent influenza vaccine microneedle intradermal device (FluGen Inc)

NeuSpera Medical Inc.

United States

ANM Adaptive Neuromodulation GmbH

Germany

Medlogics Device Corporation

United States

Battery-Free Sacral Neuromodulation Device Shows 84% Success Rate in Treating Urinary Incontinence

FDA Approves First Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

Axonics R20 Sacral Neuromodulation System Gains Australian Regulatory Approval